Compare · ESLA vs MRNA
ESLA vs MRNA
Side-by-side comparison of Estrella Immunopharma Inc. (ESLA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESLA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $94.42B, about 4055.8x ESLA ($23.3M).
- MRNA has been more active in the news (11 items in the past 4 weeks vs 2 for ESLA).
- MRNA has more recent analyst coverage (25 ratings vs 0 for ESLA).
- Company
- Estrella Immunopharma Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $23.3M
- $94.42B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 2
- 11
- Recent ratings
- 0
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ESLA
- Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
- Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
- Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CEO Liu Cheng exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 34% to 397,437 units (SEC Form 4)
- Chief Financial Officer Xu Jiandong exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 38% to 365,488 units (SEC Form 4)
- Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Amendment: SEC Form SCHEDULE 13G/A filed by Estrella Immunopharma Inc.
- SEC Form 10-Q filed by Estrella Immunopharma Inc.
- Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
- Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology